Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Teva Pharmaceuticals has launched a new patient access program in partnership with Direct Relief to provide free inhalers to uninsured patients in the United States. The program, running for a minimum of three years, will supply two generic inhaler products: generic versions of AirDuo®RespiClick® (maintenance inhaler) and ProAir® HFA (rescue inhaler).
The initiative aims to address accessibility issues for uninsured patients, as while 93% of Teva's inhaler medicines are generic products with lower prices for insured patients, uninsured individuals still face affordability challenges. Teva will donate the inhalers to Direct Relief for distribution through their network of free and charitable clinics. Additionally, Teva will provide a cash donation to cover program administration costs.
Teva Pharmaceuticals ha lanciato un nuovo programma di accesso per i pazienti in collaborazione con Direct Relief per fornire inalatori gratuiti ai pazienti non assicurati negli Stati Uniti. Il programma, che avrà una durata minima di tre anni, fornirà due prodotti inalatori generici: versioni generiche di AirDuo® RespiClick® (inalatore di mantenimento) e ProAir® HFA (inalatore d'emergenza).
L'iniziativa mira a affrontare i problemi di accessibilità per i pazienti non assicurati, poiché, mentre il 93% dei farmaci inalatori di Teva sono prodotti generici con prezzi più bassi per i pazienti assicurati, gli individui non assicurati continuano a affrontare difficoltà economiche. Teva donerà gli inalatori a Direct Relief per la distribuzione attraverso la loro rete di cliniche gratuite e caritatevoli. Inoltre, Teva fornirà una donazione in denaro per coprire i costi di amministrazione del programma.
Teva Pharmaceuticals ha lanzado un nuevo programa de acceso para pacientes en colaboración con Direct Relief para ofrecer inhaladores gratuitos a pacientes no asegurados en los Estados Unidos. El programa, que se ejecutará durante un mínimo de tres años, suministrará dos productos inhaladores genéricos: versiones genéricas de AirDuo® RespiClick® (inhalador de mantenimiento) y ProAir® HFA (inhalador de rescate).
La iniciativa tiene como objetivo abordar los problemas de accesibilidad para los pacientes no asegurados, ya que, aunque el 93% de los medicamentos inhaladores de Teva son productos genéricos con precios más bajos para los pacientes asegurados, las personas no aseguradas aún enfrentan desafíos de asequibilidad. Teva donará los inhaladores a Direct Relief para su distribución a través de su red de clínicas gratuitas y benéficas. Además, Teva proporcionará una donación en efectivo para cubrir los costos de administración del programa.
테바 제약이 Direct Relief와 협력하여 미국 내 보험이 없는 환자들에게 무료 흡입기를 제공하는 새 환자 접근 프로그램을 시작했습니다. 이 프로그램은 최소 3년 동안 진행되며, 유지용 흡입기인 AirDuo® RespiClick®와 구급용 흡입기인 ProAir® HFA의 두 가지 제네릭 흡입기 제품을 공급할 예정입니다.
이 이니셔티브는 보험이 없는 환자들의 접근성 문제를 해결하는 것을 목표로 하고 있습니다. 테바의 흡입기 의약품 93%가 보험이 있는 환자에게 더 저렴한 가격의 제네릭 제품이지만, 보험이 없는 개인은 여전히 비용 부담 문제에 직면하고 있습니다. 테바는 흡입기를 Direct Relief에 기부하여 그들의 무료 및 자선 클리닉 네트워크를 통해 배포할 것입니다. 또한, 테바는 프로그램 운영 비용을 충당하기 위해 현금 기부도 할 예정입니다.
Teva Pharmaceuticals a lancé un nouveau programme d'accès pour les patients en partenariat avec Direct Relief pour fournir des inhalateurs gratuits aux patients non assurés aux États-Unis. Le programme, qui durera au moins trois ans, fournira deux produits inhalateurs génériques : des versions génériques d'AirDuo® RespiClick® (inhalateur d'entretien) et de ProAir® HFA (inhalateur de secours).
L'initiative vise à résoudre les problèmes d'accessibilité pour les patients non assurés, car bien que 93 % des médicaments inhalatoires de Teva soient des produits génériques avec des prix plus bas pour les patients assurés, les personnes non assurées continuent de faire face à des défis d'accessibilité financière. Teva fera don des inhalateurs à Direct Relief pour une distribution via leur réseau de cliniques gratuites et caritatives. De plus, Teva fournira un don en espèces pour couvrir les coûts administratifs du programme.
Teva Pharmaceuticals hat ein neues Patienten-Zugang-Programm in Partnerschaft mit Direct Relief ins Leben gerufen, um uninsured Patienten in den USA kostenlose Inhalatoren zur Verfügung zu stellen. Das Programm, das mindestens drei Jahre laufen wird, stellt zwei generische Inhalatorprodukte zur Verfügung: generische Versionen von AirDuo® RespiClick® (Erhaltungsinhalator) und ProAir® HFA (Notfallinhalator).
Die Initiative zielt darauf ab, die Zugänglichkeitsprobleme für uninsured Patienten zu adressieren, da 93 % von Tevas Inhalator-Medikamenten generische Produkte mit niedrigeren Preisen für versicherte Patienten sind, uninsured Personen jedoch weiterhin mit Erschwinglichkeitsproblemen konfrontiert sind. Teva wird die Inhalatoren an Direct Relief spenden, die sie über ihr Netzwerk von kostenlosen und karitativen Kliniken verteilen werden. Darüber hinaus wird Teva eine Geldspende bereitstellen, um die Verwaltungskosten des Programms zu decken.
- Three-year commitment ensures stable supply of essential medications
- Program expands market reach into underserved communities
- Partnership with established distributor (Direct Relief) reduces operational costs
- None.
Insights
This charitable initiative, while commendable from a social responsibility perspective, has minimal direct financial impact on Teva's bottom line or stock performance. The program targets a small segment of uninsured patients through charitable clinics, involving only two generic inhaler products. While it may generate some positive PR and strengthen Teva's relationship with healthcare providers, the donation scale is unlikely to materially affect the company's
The three-year commitment demonstrates long-term planning in addressing healthcare accessibility, but from an investor standpoint, the program's costs, including product donations and administrative funding to Direct Relief, represent a minor operational expense. The initiative aligns with industry trends toward expanded patient access programs but doesn't significantly alter Teva's market position in the respiratory medicine space.
The strategic timing of this program launch coincides with increasing public focus on healthcare accessibility and rising drug costs. While the program enhances Teva's ESG profile and could potentially strengthen its market presence in the generic respiratory medication segment, where they already hold
- Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics
- The program, launching this month, will run for a minimum of three years
PARSIPPANY, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a new patient access program, in partnership with Direct Relief, to supply inhalers to eligible patients in the United States free of charge.
“In the United States, while
Teva will make two inhaler products available through this program: generic versions of the AirDuo®RespiClick® (fluticasone propionate/salmeterol xinafoate maintenance inhaler) and ProAir® HFA (albuterol sulfate rescue inhaler). Teva will donate the inhalers to Direct Relief for distribution by request to free & charitable clinics, to then be dispensed to uninsured patients served by these clinics.
"Direct Relief is deeply grateful to Teva for this critical donation which will connect patients with respiratory treatments they otherwise would not have access to," said Katie Lewis, Regional Director, U.S. Programs for Direct Relief. "Free and charitable clinics offer quality care for underserved communities, and this donation will allow them to reach even more patients with these medications."
The program will continue for a minimum of three years to ensure reliable and continuous supply to these patients. In addition to donating the inhalers, Teva will make a cash donation to Direct Relief to cover the costs of administering this program.
Direct Relief, Teva’s long-time partner on access to medicines programs in the U.S. and around the world, is a nonprofit humanitarian organization that provides medical resources to resource-poor communities. It operates, by its own account, the largest charitable medicine program in the United States. Through its network, Direct Relief supports the dispensing of high-quality, no-cost medicines to low-income, uninsured patients at the point of care, thereby facilitating patient access to necessary medicines.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our to successfully make our two inhaler products available through the new patient access program; our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our substantial indebtedness; our business and operations in general including the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
| IR Contacts | |||
| PR Contacts | United States | Kelley Dougherty | (973) 658-0237 |
| Israel | Yonatan Beker Eden Klein | (973) 264 7378 972 (3) 906-2645 | |
|
|
|
|
|
FAQ
What inhalers is TEVA providing through its new Direct Relief program?
How long will TEVA's inhaler donation program run?
Who is eligible for TEVA's free inhaler program?
What percentage of TEVA's inhaler medicines are generic products in the US?
How will TEVA's inhaler donation program be distributed?
